Status:
COMPLETED
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purposes of this study are: 1. To evaluate the long-term safety of dabigatran etexilate 2. To assess the effect of a knowledge translation intervention on patient outcomes
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Participation in RE-LY, requires long term anticoagulation, provides written informed consent
- Exclusion criteria:
- Permanent discontinuation of dabigatran during RE-LY
Exclusion
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
5897 Patients enrolled
Trial Details
Trial ID
NCT00808067
Start Date
November 1 2008
End Date
December 1 2012
Last Update
June 9 2014
Active Locations (567)
Enter a location and click search to find clinical trials sorted by distance.
1
1160.71.0046 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
2
1160.71.0057 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
3
1160.71.0211 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
4
1160.71.0115 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States